Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bristol-Myers Squibb (NY:BMY)

46.35 +0.15 (+0.32%)
Official Closing Price Updated: 4:10 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability
Bristol-Myers Squibb (BMY) offers a compelling 5.22% dividend yield with a strong history of growth, backed by high profitability and an attractive valuation. 
Via Chartmill
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Price Over Earnings Overview: Bristol-Myers Squibb
 
Via Benzinga
The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now
With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward. 
Via The Motley Fool
Topics Intellectual Property
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates. 
Via Benzinga
S&P 500 Soars to Uncharted Territory: Is the Market Overvalued or Justified by a New Era of Growth?
The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
 
Via Benzinga
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
2 Top Dividend Stocks to Buy With Less Than $50
These stocks are cheap in more ways than one. 
Via The Motley Fool
Topics Intellectual Property
2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles
September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains. 
Via Benzinga
Topics Stocks
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers. 
Via Investor's Business Daily
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Profitable Stock Worth Investigating and 2 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability and Growth Prospects
Bristol-Myers Squibb (BMY) is a top dividend stock with a 5.12% yield, strong profitability, and a solid financial health rating, making it a compelling choice for income investors. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades'
Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and Live Nation also highlighted. 
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Identified as a Top Value Stock with Strong Fundamentals
Bristol-Myers Squibb (BMY) is a top value stock with a low P/E ratio of 7.2, strong profitability, and a high 5.19% dividend yield. 
Via Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
How Do Investors Really Feel About Bristol-Myers Squibb?
 
Via Benzinga
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
The dividend stocks listed below all yield more than 5% and look like safe long-term buys. 
Via The Motley Fool
BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.